AZ
AZN.US AstraZeneca PLC
- Market cap
- USD 286B
- P/E
- 26.1x
- P/B
- 5.53x
- ROE
- 22.4%
- Dividend yield
- 1.74%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AZN.US undervalued?
Graham numberAZN.US trades 153.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AstraZeneca PLC fundamental analysis
No fundamental analysis for AstraZeneca PLC yet.
AstraZeneca PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/…
Full company profileAstraZeneca PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AstraZeneca PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.0B | 22.5B | 22.1B | 24.4B | 26.6B | 37.4B | 44.4B | 45.8B | 54.1B | 58.7B | 62.2B |
| Gross Profit | 18.9B | 18.1B | 17.2B | 19.5B | 21.3B | 25.0B | 32.0B | 37.5B | 43.9B | 48.1B | 49.9B |
| Operating Income | 4.90B | 3.68B | 3.39B | 2.92B | 5.16B | 1.06B | 3.76B | 8.19B | 10.0B | 13.7B | 15.6B |
| EBITDA | 7.28B | 6.62B | 7.11B | 6.71B | 8.08B | 5.11B | 9.09B | 13.4B | 15.4B | 19.8B | 22.3B |
| Net Income | 3.50B | 3.00B | 2.16B | 1.34B | 3.20B | 112M | 3.29B | 5.96B | 7.04B | 10.3B | 11.5B |
| EPS | 2.76 | 2.37 | 1.70 | 1.03 | 2.43 | 0.08 | 2.11 | 3.81 | 4.50 | 6.57 | 7.40 |
| Balance Sheet | |||||||||||
| Total Assets | 62.5B | 63.4B | 60.7B | 61.4B | 66.7B | 105B | 96.5B | 101B | 104B | 114B | 120B |
| Total Liabilities | 45.9B | 46.7B | 46.6B | 46.8B | 51.1B | 66.1B | 59.4B | 62.0B | 63.2B | 65.4B | 68.0B |
| Shareholders' Equity | 14.9B | 15.0B | 12.5B | 13.1B | 15.6B | 39.3B | 37.0B | 39.1B | 40.8B | 48.7B | 51.6B |
| Cash & Short-term Investments | 5.90B | 4.55B | 5.68B | 6.22B | 7.99B | 6.40B | 6.24B | 5.86B | 5.53B | 5.74B | 8.15B |
| Total Debt | 16.8B | 17.8B | 19.1B | 18.2B | 20.4B | 30.7B | 29.1B | 28.6B | 30.1B | 29.7B | 34.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.15B | 3.58B | 2.62B | 2.97B | 4.80B | 5.96B | 9.81B | 10.3B | 11.9B | 14.6B | 14.5B |
| Capital Expenditure | 2.31B | 1.62B | 1.37B | 2.46B | 2.61B | 2.20B | 2.57B | 3.78B | 4.59B | 5.91B | 3.94B |
| Free Cash Flow | 1.83B | 1.96B | 1.25B | 509M | 2.19B | 3.76B | 7.24B | 6.57B | 7.28B | 8.67B | 10.6B |
| Ratios | |||||||||||
| ROE | 23.6% | 20.1% | 17.3% | 10.2% | 20.5% | 0.3% | 8.9% | 15.2% | 17.2% | 21.1% | 22.4% |
| ROA | 5.6% | 4.7% | 3.6% | 2.2% | 4.8% | 0.1% | 3.4% | 5.9% | 6.8% | 9.0% | 9.6% |
| Net Profit Margin | 15.2% | 13.4% | 9.8% | 5.5% | 12.0% | 0.3% | 7.4% | 13.0% | 13.0% | 17.5% | 18.6% |
| Debt to Equity | 1.13x | 1.19x | 1.53x | 1.39x | 1.30x | 0.78x | 0.79x | 0.73x | 0.74x | 0.61x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AstraZeneca PLC dividends
- Dividend yield
- 1.74%
- Forward dividend
- 3.20 USD
- Payout ratio
- 48.5%
- Ex-dividend date
- Aug 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.97B | 3.18 | 48.5% |
| 2024 | USD 4.63B | 2.96 | 65.8% |
| 2023 | USD 4.48B | 2.87 | 75.2% |
| 2022 | USD 4.36B | 2.80 | 132.7% |
| 2021 | USD 3.86B | 2.70 | 3,442.9% |
| 2020 | USD 3.57B | 2.72 | 111.8% |
| 2019 | USD 3.59B | 2.76 | 269.1% |
| 2018 | USD 3.48B | 2.75 | 161.7% |
| 2017 | USD 3.52B | 2.78 | 117.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2 on Feb 2, 2026.
Who owns AstraZeneca PLC
- Insiders 0.05%
- Institutions 76.13%
- Public & others 23.82%
- Shares outstanding 1.55B
- Free float 1.54B
Top funds holding AZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Total Intl Stock Index Inv | 22.2M | 1.43% | +0.29% | Sep 2026 |
| Vanguard Developed Markets Index Admiral | 14.6M | 0.94% | -0.34% | Sep 2026 |
| Vanguard PRIMECAP Inv | 11.9M | 0.77% | +0.04% | Sep 2026 |
| iShares Core MSCI EAFE ETF | 11.5M | 0.74% | 0.00% | Oct 2026 |
| American Funds New Perspective A | 11.3M | 0.73% | -33.17% | Sep 2026 |
| PUTM ACS UK All Shr Lstd EqMultiMgrB£Acc | 10.2M | 0.66% | +7.57% | Oct 2026 |
| Vanguard Health Care Inv | 10.2M | 0.66% | +0.90% | Sep 2026 |
| Goldman Sachs GQG Ptnrs Intl Opps Instl | 10.1M | 0.65% | 0.00% | Jun 2026 |
| iShares Core FTSE 100 ETF GBP Dist | 9.75M | 0.63% | 0.00% | Oct 2026 |
| Vanguard FTSE UK All Shr Idx Unit Tr£Acc | 9.01M | 0.58% | -0.15% | Sep 2026 |
| iShares UK Equity Index (UK) L Acc | 7.91M | 0.51% | +1.71% | Sep 2026 |
| American Funds EUPAC A | 7.66M | 0.49% | -22.37% | Sep 2026 |
| American Funds Capital Inc Bldr A | 7.36M | 0.47% | -4.44% | Sep 2026 |
| Fidelity International Index | 5.99M | 0.39% | +0.40% | Sep 2026 |
| iShares MSCI EAFE ETF | 5.42M | 0.35% | 0.00% | Oct 2026 |
| FID DC L&G LB UK Equity Index N | 4.70M | 0.30% | -3.85% | Sep 2026 |
| Vanguard Equity-Income Inv | 4.43M | 0.29% | +61.14% | Sep 2026 |
| American Funds Income Fd of Amer A | 4.20M | 0.27% | -7.54% | Sep 2026 |
| Vanguard FTSE 100 UCITS ETF | 3.85M | 0.25% | +0.36% | Sep 2026 |
| L&G UK Index I Acc | 3.83M | 0.25% | 0.00% | Aug 2026 |
Top institutions holding AZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Investors Finance Co PLC | 51.6M | 3.33% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 45.4M | 2.93% | +0.77% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 34.6M | 2.23% | +0.53% | Jun 2026 |
| NORGES BANK | 33.9M | 2.18% | 0.00% | Jun 2026 |
| Capital World Investors | 30.1M | 1.94% | +6.41% | Jun 2026 |
| FMR Inc | 28.9M | 1.86% | -2.39% | Jun 2026 |
| Wellington Management Company LLP | 28.5M | 1.84% | +20.15% | Jun 2026 |
| Legal & General Group PLC | 25.8M | 1.66% | -0.39% | Jun 2026 |
| JPMorgan Chase & Co | 19.2M | 1.24% | +3.30% | Jun 2026 |
| VANGUARD ASSET MANAGEMENT Ltd | 18.7M | 1.21% | +0.96% | Jun 2026 |
| PRIMECAP Management Company | 18.1M | 1.17% | -0.65% | Jun 2026 |
| Bank of America Corp | 17.7M | 1.14% | -7.18% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 16.6M | 1.07% | -14.74% | Jun 2026 |
| Franklin Templeton Inc | 16.5M | 1.06% | -7.20% | Jun 2026 |
| Amundi | 16.4M | 1.06% | +6.74% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 13.3M | 0.86% | +0.73% | Jun 2026 |
| Deutsche Bank AG | 12.6M | 0.82% | +4.21% | Jun 2026 |
| Jupiter Topco LLC | 11.9M | 0.77% | 0.00% | Jun 2026 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 11.7M | 0.76% | -9.41% | Jun 2026 |
| Fisher Asset Management, LLC | 11.1M | 0.72% | +2.77% | Jun 2026 |
AstraZeneca PLC company profile
- Company name
- AstraZeneca PLC
- Ticker
- AZN.US
- ISIN
- GB0009895292
- Exchange
- USA Stocks
- Listed since
- May 17, 1993
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 96,100
- Fiscal year end
- December
- Address
- 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
- Phone
- 44 20 3749 5000
- Website
- astrazeneca.com
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
AstraZeneca PLC management
10- Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.CEO & Executive Director · born 1959
- Dr. Aradhana Sarin M.D.CFO & Executive Director · born 1974
- Ms. Pam P. ChengEVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board · born 1970
- Mr. Joris SilonHead of Investor Relations
- Mr. Jeffrey Pott J.D.CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
- Dr. Ruud Dobber Ph.D.Executive Vice-President of BioPharmaceuticals Business Unit
- Dr. Susan Mary Galbraith M.D., Ph.D.Executive Vice President of Oncology R&D · born 1966
- Ms. Iskra ReicExecutive Vice President of International
- Mr. David FredricksonExecutive Vice-President of Oncology Haematology Business Unit · born 1975
- Ms. Ruth March FMEDSCI, O.B.E., Ph.D.Senior VP of Precision Medicine - R&D Oncology